Advertisement
Screener

SYNLOGIC, INC. (SYBX) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

SYNLOGIC, INC. Research and Development Expense

SYNLOGIC, INC. (SYBX) reported Research and Development Expense of $49.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-05-14

  • SYNLOGIC, INC. research and development expense for the quarter ending 2026-03-31 was $49.00K, a 122.73% increase year-over-year.
  • SYNLOGIC, INC. research and development expense for the quarter ending 2025-03-31 was $22.00K, a 99.71% decline year-over-year.
  • SYNLOGIC, INC. research and development expense for the quarter ending 2024-06-30 was $2.20M, a 81.33% decline year-over-year.
  • SYNLOGIC, INC. research and development expense for the quarter ending 2024-03-31 was $7.68M, a 38.31% decline year-over-year.
  • SYNLOGIC, INC. research and development expense for fiscal 2025 was $43.00K, a 99.53% decline from fiscal 2024.
  • SYNLOGIC, INC. research and development expense for fiscal 2024 was $9.15M, a 79.18% decline from fiscal 2023.
  • SYNLOGIC, INC. research and development expense for fiscal 2023 was $43.97M, a 15.51% decline from fiscal 2022.
  • SYNLOGIC, INC. research and development expense for fiscal 2022 was $52.04M, a 10.43% increase from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filed
2026-03-31$49.00K
10-Q · filed 2026-05-14
2025-12-31$43.00K
10-K · filed 2026-03-12
2025-03-31$22.00K
10-Q · filed 2026-05-14
2024-12-31$9.15M
10-K · filed 2026-03-12
2024-06-30$2.20M
10-Q · filed 2024-08-08
$9.88M
10-Q · filed 2024-08-08
$20.02M
derived: sum of 3 quarters · filed 2025-05-08
$29.63M
derived: sum of 4 quarters · filed 2025-05-08
2024-03-31$7.68M
10-Q · filed 2025-05-08
$17.82M
derived: sum of 2 quarters · filed 2025-05-08
$27.44M
derived: sum of 3 quarters · filed 2025-05-08
$39.20M
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31$10.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06
$19.76M
derived: sum of 2 quarters · filed 2025-03-06
$31.52M
derived: sum of 3 quarters · filed 2025-03-06
$43.97M
10-K · filed 2025-03-06
2023-09-30$9.62M
10-Q · filed 2023-11-09
$21.38M
derived: sum of 2 quarters · filed 2024-08-08
$33.83M
10-Q · filed 2023-11-09
$47.47M
derived: sum of 4 quarters · filed 2024-08-08
2023-06-30$11.77M
10-Q · filed 2024-08-08
$24.21M
10-Q · filed 2024-08-08
$37.85M
derived: sum of 3 quarters · filed 2024-08-08
$52.46M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$12.45M
10-Q · filed 2024-05-14
$26.09M
derived: sum of 2 quarters · filed 2024-05-14
$40.70M
derived: sum of 3 quarters · filed 2024-05-14
$52.76M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$13.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19
$28.25M
derived: sum of 2 quarters · filed 2024-03-19
$40.31M
derived: sum of 3 quarters · filed 2024-03-19
$52.04M
10-K · filed 2024-03-19
2022-09-30$14.61M
10-Q · filed 2023-11-09
$26.67M
derived: sum of 2 quarters · filed 2023-11-09
$38.41M
10-Q · filed 2023-11-09
$50.28M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30$12.06M
10-Q · filed 2023-08-10
$23.80M
10-Q · filed 2023-08-10
$35.67M
derived: sum of 3 quarters · filed 2023-08-10
$49.02M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$11.74M
10-Q · filed 2023-05-11
$23.61M
derived: sum of 2 quarters · filed 2023-05-11
$36.97M
derived: sum of 3 quarters · filed 2023-05-11
$47.69M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$11.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29
$25.23M
derived: sum of 2 quarters · filed 2023-03-29
$35.95M
derived: sum of 3 quarters · filed 2023-03-29
$47.13M
10-K · filed 2023-03-29
2021-09-30$13.36M
10-Q · filed 2022-11-10
$24.07M
derived: sum of 2 quarters · filed 2022-11-10
$35.25M
10-Q · filed 2022-11-10
$46.66M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30$10.72M
10-Q · filed 2022-08-11
$21.90M
10-Q · filed 2022-08-11
$33.31M
derived: sum of 3 quarters · filed 2022-08-11
$43.79M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31$11.18M
10-Q · filed 2022-05-12
$22.59M
derived: sum of 2 quarters · filed 2022-05-12
$33.07M
derived: sum of 3 quarters · filed 2022-05-12
$45.98M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31$11.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
$21.89M
derived: sum of 2 quarters · filed 2022-03-17
$34.80M
derived: sum of 3 quarters · filed 2022-03-17
$47.47M
10-K · filed 2022-03-17
2020-09-30$10.48M
10-Q · filed 2021-11-10
$23.39M
derived: sum of 2 quarters · filed 2021-11-10
$36.07M
10-Q · filed 2021-11-10
$47.32M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$12.91M
10-Q · filed 2021-08-12
$25.59M
10-Q · filed 2021-08-12
$36.84M
derived: sum of 3 quarters · filed 2021-08-12
$47.40M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31$12.68M
10-Q · filed 2021-05-13
$23.93M
derived: sum of 2 quarters · filed 2021-05-13
$34.49M
derived: sum of 3 quarters · filed 2021-05-13
$44.20M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31$11.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
$21.82M
derived: sum of 2 quarters · filed 2021-03-25
$31.52M
derived: sum of 3 quarters · filed 2021-03-25
$41.91M
10-K · filed 2021-03-25
2019-09-30$10.56M
10-Q · filed 2020-11-05
$20.27M
derived: sum of 2 quarters · filed 2020-11-05
$30.65M
10-Q · filed 2020-11-05
$39.52M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$9.70M
10-Q · filed 2020-08-06
$20.09M
10-Q · filed 2020-08-06
$28.95M
derived: sum of 3 quarters · filed 2020-08-06
$38.89M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31$10.38M
10-Q · filed 2020-05-08
$19.25M
derived: sum of 2 quarters · filed 2020-05-08
$29.18M
derived: sum of 3 quarters · filed 2020-05-08
$40.06M
derived: sum of 4 quarters · filed 2020-05-08
2018-12-31$8.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$18.80M
derived: sum of 2 quarters · filed 2020-03-12
$29.67M
derived: sum of 3 quarters · filed 2020-03-12
$38.03M
10-K · filed 2020-03-12
2018-09-30$9.93M
10-Q · filed 2019-11-12
$20.81M
derived: sum of 2 quarters · filed 2019-11-12
$29.17M
10-Q · filed 2019-11-12
$36.90M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$10.87M
10-Q · filed 2019-08-08
$19.23M
10-Q · filed 2019-08-08
$26.97M
derived: sum of 3 quarters · filed 2019-08-08
$35.92M
derived: sum of 4 quarters · filed 2019-08-08
2018-03-31$8.36M
10-Q · filed 2019-05-09
$16.10M
derived: sum of 2 quarters · filed 2019-05-09
$25.05M
derived: sum of 3 quarters · filed 2019-05-09
$33.58M
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31$7.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12
$16.69M
derived: sum of 2 quarters · filed 2019-03-12
$25.22M
derived: sum of 3 quarters · filed 2019-03-12
$30.34M
10-K · filed 2019-03-12
2017-09-30$8.96M
10-Q · filed 2018-11-13
$17.49M
derived: sum of 2 quarters · filed 2018-11-13
$22.61M
10-Q · filed 2018-11-13
$24.95M
derived: sum of 4 quarters · filed 2018-11-13
2017-06-30$8.53M
10-Q · filed 2018-08-09
$5.08M
10-Q · filed 2017-08-04
$13.65M
10-Q · filed 2018-08-09
$5.32M
10-Q · filed 2017-08-04
$15.99M
derived: sum of 3 quarters · filed 2018-08-09
$20.12M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31$5.12M
10-Q · filed 2018-05-15
$242.00K
10-Q · filed 2017-05-09
$7.46M
derived: sum of 2 quarters · filed 2018-05-15
$11.59M
derived: sum of 3 quarters · filed 2018-05-15
$15.27M
derived: sum of 4 quarters · filed 2018-05-15
2016-12-31$2.34M
10-K · filed 2017-03-15
$6.47M
derived: sum of 2 quarters · filed 2017-11-13
$10.16M
derived: sum of 3 quarters · filed 2017-11-13
$15.01M
10-K · filed 2018-03-20
$13.93M
10-K · filed 2017-03-15
2016-09-30$4.13M
10-Q · filed 2017-11-13
$3.38M
10-Q · filed 2016-11-10
$7.82M
derived: sum of 2 quarters · filed 2017-11-13
$9.88M
10-Q · filed 2017-11-13
$11.59M
10-Q · filed 2016-11-10
$18.70M
derived: sum of 4 quarters · filed 2017-11-13
2016-06-30$3.68M
10-Q · filed 2017-08-04
$8.21M
10-Q · filed 2017-08-04
$14.57M
derived: sum of 3 quarters · filed 2017-08-04
$19.25M
derived: sum of 4 quarters · filed 2017-08-04
2016-03-31$4.52M
10-Q · filed 2017-05-09
$10.89M
derived: sum of 2 quarters · filed 2017-05-09
$15.57M
derived: sum of 3 quarters · filed 2017-05-09
$20.07M
derived: sum of 4 quarters · filed 2017-05-09
2015-12-31$6.36M
10-K · filed 2017-03-15
$11.05M
derived: sum of 2 quarters · filed 2017-03-15
$15.54M
derived: sum of 3 quarters · filed 2017-03-15
$18.95M
10-K · filed 2017-03-15
2015-09-30$4.68M
10-K · filed 2017-03-15
$9.18M
derived: sum of 2 quarters · filed 2017-03-15
$12.58M
10-Q · filed 2016-11-10
$16.09M
derived: sum of 4 quarters · filed 2017-03-15
2015-06-30$4.50M
10-K · filed 2017-03-15
$7.90M
10-Q · filed 2016-08-15
$11.40M
derived: sum of 3 quarters · filed 2017-03-15
$14.19M
derived: sum of 4 quarters · filed 2017-03-15
2015-03-31$3.40M
10-K · filed 2017-03-15
$6.90M
derived: sum of 2 quarters · filed 2017-03-15
$9.69M
derived: sum of 3 quarters · filed 2017-03-15
$11.76M
derived: sum of 4 quarters · filed 2017-03-15
2014-12-31$3.50M
10-K · filed 2016-03-30
$6.29M
derived: sum of 2 quarters · filed 2016-03-30
$8.36M
derived: sum of 3 quarters · filed 2016-03-30
$10.54M
10-K · filed 2017-03-15
2014-09-30$2.79M
10-K · filed 2016-03-30
$4.86M
derived: sum of 2 quarters · filed 2016-03-30
$7.04M
10-Q · filed 2015-11-13
2014-06-30$2.07M
10-K · filed 2016-03-30
$4.26M
derived: sum of 2 quarters · filed 2016-03-30
2014-03-31$2.19M
10-K · filed 2016-03-30
2013-12-31$4.39M
10-K · filed 2016-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26
Enveric Biosciences, Inc. (ENVB)United States$0.007B-0.63
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
Pulmatrix, Inc. (PULM)United States$0.006B
EXICURE, INC. (XCUR)United States$0.008B-1.54